Clinical Profile and Treatment Evaluation of Rifampicin-Resistant and Multidrug-Resistant Tuberculosis Patients at Dr. Kanujoso Djatiwibowo Public Hospital, Balikpapan
DOI:
https://doi.org/10.36497/jri.v38i3.2Keywords:
Multidrug-resistant tuberculosis, Rifampicin-resistant, Clinical profile, PMDT, MTPROAbstract
Background: Rifampicin-resistant (RR-TB) and multidrug-resistant tuberculosis (MDR-TB) remains a major health problem worldwide and in Indonesia also become a challenge in total eradication of tuberculosis. Dr. Kanujoso Djatiwibowo Public Hospital (RSKD) Balikpapan is one of the two referral hospitals in East Kalimantan for evaluation and initiation of MDR-TB treatment. The objective of this study is to evaluate clinical profile and treatment of RR-TB and MDR-TB patients at RSKD. Methods: A retrospective cross-sectional study was conducted using data from eTB manager database and medical record of RR-TB and MDR-TB at RSKD from January 2013 to October 2016. Results: Twenty eight RR-TB and MDR-TB patients, most of them were female (53.6%), belong to 35-44 age group (28.6%), housewife (25%), graduated from senior high school (42,9%), malnutrition (28.6%), and relapse cases (50%). Diabetes mellitus and anemia were found in 42,9% and 44.4% of the patients, respectively. The most resistant pattern is rifampicin-resistant TB (57,1%) followed by rifampicin and isoniazid resistant. The most common side effect of TB treatment was gastrointestinal complaints (44.4%). The success rate of MDRTB treatment at RSKD was 20%, followed by 20% mortality, 50% of lost to follow up, 10% of treatment failure, and there are 8 patients still ongoing therapy. Conclusion: Most of the RR-TB and MDR-TB cases were relapse cases. Counseling, education, and support for the patients undergoing MDR-TB treatment are strongly needed to increase success rate and decreasing number of lost to follow up.Downloads
References
World Health Organization. Global tuberculosis report. [Online]. 2016 [Cited 2016 November 1]. Available from: http://apps.who.int/iris/bitstream/10665/250441/1/9789241565394-eng.pdf?ua=1.
World Health Organization. Global tuberculosis report. [Online]. 2014 [Cited 2016 November 1]. Available from: http://apps.who.int/iris/itstream/10665/137094/1/9789241564809_eng.pdf.
Kementerian Kesehatan Republik Indonesia. Info datin tuberkulosis. [Online]. 2015 [Cited 2016 November 2]. Available from: http://www.depkes.go.id/resources/download/pusdatin/infodatin/infodatin_tb.pdf.
World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis. [Online]. 2016 [Cited 2016 November 1]. Available from: http://www.who.int/tb/MDRTBguidelines2016.pdf.
Kementerian Kesehatan Republik Indonesia Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan. Pedoman nasional
pengendalian tuberkulosis. [Online]. 2014 [Cited 2016 November 1]. Available from: http://www.tbindonesia.or.id/opendir/Buku/bpn_p-tb_2014.pdf.
Sinaga BYM. Karakteristik pasien multi drug resistant tuberculosis yang mengikuti programmatic management of drug resistant tuberculosis di
Rumah Sakit Umum Pusat H. Adam Malik Medan. J Respir Indo. 2013;33:221-8.
Munir SM, Nawas A, Soetoyo DK. Pengamatan pasien tuberkulosis paru dengan multidrug resistant (TB MDR) di poliklinik paru RSUP
Persahabatan. J Respir Indo. 2008;30:92-104.
Elmi OS, Hasan H, Abdullah S, Mat Jeab MZ, Bin Alwi Z, Naing NN. Multidrug-resistant tuberculosis and risk factors associated with its development: a retrospective study. J Infect Dev Ctries. 2015;9:1076-85.
Nurjana MA. Faktor risiko terjadinya tuberculosis paru usia produktif (15-49 tahun) di Indonesia. Media Penelitian dan Pengembangan Kesehatan. 2015;25:163-70.
Chung-Delgado K, Guillen-Bravo S, Revilla- Montag A, Bernabe-Ortiz A. Mortality among MDR-TB Cases: Comparison with Drug-Susceptible
Tuberculosis and Associated Factors. PLoS One. 2015;10:e0119332.
Akaputra R, Burhan E, Nawas A. Karakteristik dan evaluasi perjalanan penyakit multidrug resistant tuberculosis dengan diabetes melitus dan non diabetes melitus. J Respir Indo. 2008;33:92-102.
Bashar M, Alcabes P, Rom WN, Condos R. Increased incidence of multidrug-resistant tuberculosis in diabetic patients on the Bellevue Chest Service, 1987 to 1997. Chest. 2001;120:1514-9.
Fisher-Hoch SP, Whitney E, McCormick JB, Crespo G, Smith B, Rahbar MH, et al. Type 2 diabetes and multi-drug resistant tuberculosis. Scand J Infect Dis. 2008;40:888-93.
Lee SW, Kang YA, Yoon YS, Um SW, Lee SM, Yoo CG, et al. The prevalence and evolution of anemia associated with tuberculosis. J Korean Med Sci. 2006;21:1028-32.
Faustini A, Hall AJ, Perucci CA. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax. 2006;61:158-63.
Kementerian Kesehatan Republik Indonesia Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan. Petunjuk teknis manajemen terpadu pengendalian tuberkulosis resistan obat. Jakarta: Kemenkes RI; 2015.
World Health Organization. Ethical issues in tuberculosis prevention, care, and control [Online]. 2014 [Cited 2016 November 5]. Available from: http://www.who.int/tb/publications/ethics_in_tb_factsheet_28jan11rev.pdf.
Van der Walt M, Lancaster J, Odendaal R, Davis JG, Shean K, Farley J. Serious treatment related adverse drug reactions amongst anti-retroviral naive MDR-TB patients. PLoS One. 2013;8:e58817.
Tag El Din MA, El Maraghy AA, Abdel Hay AHR. Adverse reactions among patients being treated for multi-drug resistant tuberculosis at Abbassia Chest Hospital. Egypt J Chest Dis Tuberc. 2015;64:939-52.
Kusnanto P, Eko V, Pakiding H, Nurwidiasih D. Multidrug resistant tuberculosis (MDR-TB): tinjauan epidemiologi dan faktor risiko efek samping obat anti tuberkulosis. Majalah Kedokteran Bandung. 2014;46:189-96.
Chhabra N, Aseri ML, Dixit R, Gaur S. Pharmacotherapy for multidrug resistant tuberculosis. J Pharmacol Pharmacother. 2012;3:98-104.
Reviono W, Harsini AJ, Sutanto Y. Streptomisin dan insidens penurunan pendengaran pada pasien Multidrug Resistant Tuberculosis di Rumah Sakit Dr Moewardi. J Respir Indo. 2013;33:167-72.
Bhardwaj P, Deshkar AM, Verma R. Side effects encountered in treatment of multidrug-resistant tuberculosis: A 3-year experience at first dots plus site of Chhattisgarh. Int J Sci Stud. 2015;3:104-7.
Pham AQ, Doan A, Andersen M. Pyrazinamide induced hyperuricemia. Pharmacy and Therapeutics. 2014;39:695-715.
Arbex MA, Varella Mde C, Siqueira HR, Mello FA. Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 1: firstline drugs. J Bras Pneumol. 2010;36:626-40.
World Health Organization. Global tuberculosis report. [Online]. 2016 [Cited 2016 November 1]. Available from: http://www.who.int/tb/publications/global_report/gtbr2016_annex2.pdf?ua=1.
Tola HH, Tol A, Shojaeizadeh D, Garmaroudi G. Tuberculosis Treatment Non-Adherence and Lost to Follow Up among TB Patients with or without HIV in Developing Countries: A Systematic Review. Iranian J Public Health. 2015;44:1-11.
Downloads
Published
Issue
Section
License
- The authors own the copyright of published articles. Nevertheless, Jurnal Respirologi Indonesia has the first-to-publish license for the publication material.
- Jurnal Respirologi Indonesia has the right to archive, change the format and republish published articles by presenting the authors’ names.
- Articles are published electronically for open access and online for educational, research, and archiving purposes. Jurnal Respirologi Indonesia is not responsible for any copyright issues that might emerge from using any article except for the previous three purposes.
